Justification: Keloid scars are a major medical and cosmetic problem, especially in darker skin types that predominate in Mexico. It is estimated that hypertrophic scars affecting from 1.5 to 4.5% of the general population. However, the exact prevalence is unknown but studies show that going from 32 to 67%. And there are studies documenting that this prevalence is higher in Hispanic and black individuals and in the pediatric population. Keloid scars can become highly symptomatic disfiguring and which affects the quality of life of patients and their self-esteem.Problem Statement: Is silicone gel solutions superoxidation with equal or better than the gel 8% pirfenidone to treat keloids and hypertrophic scars? Goal: To evaluate the efficacy of a silicone gel-oxidation with solutions compared to a gel containing 8% pirfenidone. Hypothesis: If the silicone gel solutions superoxidation is equal or better than gel 8% pirfenidone to treat keloids and hypertrophic scars, then the reduction in the ECV and the EVA will be similar in the first group than the second. Design: Comparative, observer blind, experimental and prospective study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dermatology Life Quality Index Score
Timeframe: 3 months
Patient and Observer Scar Assessment Scale Score
Timeframe: 3 months
Vancouver Scar Scale
Timeframe: 3 months